What Do Consultants Look For When Advising Drug Development Companies On CRO Selection?

By Rob Wright

L.E.K., founded in 1983, is a global strategy consulting firm with offices across Europe, the Americas, and Asia-Pacific. One of its more than 900 employees, Jonathan Kfoury, functions as the VP of L.E.K.’s Boston office, with a focus on R&D, partnership, and commercialization strategy development for biopharmaceutical and medical technology companies. With over 13 years of industry experience, Kfoury has worked as a business development executive for companies such as Acusphere and Purdue Pharma, as well as serving as the manager of global clinical development for Cubist Pharmaceuticals’ antibiotic Cubicin. Given his wealth of experience and the increasing trend of outsourcing drug development R&D, Life Science Leader magazine reached out to Kfoury for advice on how he counsels pharmaceutical and biotech companies through the contract research organization (CRO) selection process.